Singapore GDP Growth Surges in 2025 but Outlook Remains Cautious Amid Global Trade Risks 
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Asian Markets Slip as Precious Metals Cool, Geopolitical Tensions Weigh on Sentiment 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
